PharVision Advisers’s Dynatrace DT Stock Holding History

PharVision Advisers’s Portfolio DT Stock Details DT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,267	Closed	-$484K	–	307
2025 Q1	$484K	Buy	+10,267	New	+$562K	0.67%	17

Other funds holding DT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PharVision Advisers's DT Position: Q2 2025 in Review

PharVision Advisers sold out of Dynatrace (DT) in Q2 2025, closing a stake of 10,267 shares — an estimated $484K sold.

PharVision Advisers first reported a position in DT in Q1 2025 and held it in 1 quarter. The position peaked at $484K in Q1 2025. 626 funds tracked by Wall St. Rank hold DT as of Q2 2025.

PharVision Advisers reported no remaining Dynatrace position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 10,267 Dynatrace shares in Q2 2025, an estimated $484K.
PharVision Advisers first reported a position in Dynatrace in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Dynatrace position peaked at $484K in Q1 2025.
626 funds tracked by Wall St. Rank held Dynatrace as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.